BlackRock Advisors’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

BlackRock Advisors’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$109K	Sell	1,097 -24,937	-96%	-$2.63M	﹤0.01%	3009
2016 Q3	$2.92M	Sell	26,034 -14,835	-36%	-$1.78M	﹤0.01%	1330
2016 Q2	$4.2M	Buy	40,869 +6,760	+20%	+$676K	﹤0.01%	1173
2016 Q1	$3.13M	Buy	34,109 +4,437	+15%	+$473K	﹤0.01%	1262
2015 Q4	$4.28M	Sell	29,672 -377	-1%	-$49.1K	﹤0.01%	1149
2015 Q3	$3.1M	Buy	30,049 +674	+2%	+$79K	﹤0.01%	1239
2015 Q2	$4.79M	Buy	+29,375	New	+$4.98M	0.01%	1008

Other funds holding SIOX

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock Advisors's SIOX Position: Q4 2016 in Review

BlackRock Advisors reduced its Sio Gene Therapies Inc. Common Stock (SIOX) stake by 96% in Q4 2016, selling an estimated $2.63M and leaving 1,097 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #3009.

BlackRock Advisors first reported a position in SIOX in Q2 2015 and has held it in 7 quarters since. The position peaked at $4.79M in Q2 2015. 101 funds tracked by Wall St. Rank hold SIOX as of Q4 2016.

BlackRock Advisors held 1,097 shares of Sio Gene Therapies Inc. Common Stock worth $109K as of Q4 2016.
BlackRock Advisors sold 24,937 Sio Gene Therapies Inc. Common Stock shares in Q4 2016, an estimated $2.63M.
Sio Gene Therapies Inc. Common Stock made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3009 holding.
BlackRock Advisors first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and has held it in 7 quarters since.
BlackRock Advisors's Sio Gene Therapies Inc. Common Stock position peaked at $4.79M in Q2 2015.
101 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.